tiprankstipranks
Trending News
More News >
Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
Australian Market
Advertisement

Aroa Biosurgery Ltd (ARX) AI Stock Analysis

Compare
51 Followers

Top Page

AU:ARX

Aroa Biosurgery Ltd

(Sydney:ARX)

Rating:61Neutral
Price Target:
AU$0.50
▼(-15.25%Downside)
Aroa Biosurgery Ltd's strong revenue growth and improving operational metrics are promising, but these are tempered by ongoing profitability challenges and a negative valuation outlook. Technical indicators show bullish momentum, which aids the stock's overall attractiveness despite valuation concerns.

Aroa Biosurgery Ltd (ARX) vs. iShares MSCI Australia ETF (EWA)

Aroa Biosurgery Ltd Business Overview & Revenue Model

Company DescriptionAroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
How the Company Makes MoneyAroa Biosurgery Ltd generates revenue through the sale of its soft tissue regeneration products to healthcare providers, hospitals, and clinics. The company's key revenue streams include direct sales of its advanced wound care products and surgical solutions. Aroa's products are distributed through a combination of direct sales channels and strategic partnerships with medical device distributors and healthcare entities. Additionally, the company's proprietary technology and innovation in tissue regeneration contribute to its competitive advantage and market penetration, driving sales growth and expanding its presence in international markets.

Aroa Biosurgery Ltd Financial Statement Overview

Summary
Aroa Biosurgery Ltd exhibits strong revenue growth and a solid equity position, but it struggles with profitability and free cash flow generation. Improvements in EBITDA margins indicate potential for better operational performance.
Income Statement
62
Positive
Aroa Biosurgery Ltd has demonstrated solid revenue growth, with a significant increase from 2024 to 2025. The gross profit margin is strong, indicating efficient cost management. However, persistent negative net income and EBIT margins reflect ongoing profitability challenges. The negative EBITDA margin in previous years is a concern, though it has turned positive in 2025, showing operational improvements.
Balance Sheet
70
Positive
The balance sheet is robust with a high equity ratio, suggesting financial stability and a low debt burden. The debt-to-equity ratio is favorable, highlighting prudent leverage management. However, the return on equity is negative due to net losses, indicating inefficiencies in generating shareholder returns.
Cash Flow
58
Neutral
Cash flow management shows improvement with a reduced negative operating cash flow. However, free cash flow remains negative, indicating challenges in generating sufficient cash to cover capital expenditures. The free cash flow to net income ratio is not applicable due to negative net income, but overall trends suggest gradual improvement in cash flow management.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue76.97M63.36M59.31M36.88M20.51M
Gross Profit65.99M54.10M50.06M28.17M14.25M
EBITDA2.65M-7.36M3.50M-3.75M-14.56M
Net Income-3.47M-9.75M
Balance Sheet
Total Assets98.94M101.88M109.07M104.71M73.12M
Cash, Cash Equivalents and Short-Term Investments20.13M27.73M43.00M53.35M33.93M
Total Debt5.83M6.82M6.65M5.46M14.90M
Total Liabilities14.35M14.79M13.69M11.30M19.43M
Stockholders Equity84.59M87.08M95.38M93.40M53.69M
Cash Flow
Free Cash Flow-5.69M-13.31M
Operating Cash Flow-2.33M-6.84M-10.86M-4.68M
Investing Cash Flow273.54K9.31M6.79M
Financing Cash Flow-1.34M-958.48K34.98M34.06M

Aroa Biosurgery Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.59
Price Trends
50DMA
0.52
Positive
100DMA
0.48
Positive
200DMA
0.56
Positive
Market Momentum
MACD
0.02
Positive
RSI
60.43
Neutral
STOCH
71.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ARX, the sentiment is Positive. The current price of 0.59 is above the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.52, and above the 200-day MA of 0.56, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 60.43 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ARX.

Aroa Biosurgery Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
AU$203.57M-4.06%20.36%64.81%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
$602.93M152.688.30%
$13.44B54.0220.61%<0.01%
49
Neutral
AU$148.37M-58.61%-74.88%
45
Neutral
AU$120.03M-35.20%4.68%-155.42%
41
Neutral
AU$121.04M-52.37%471.29%-4.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ARX
Aroa Biosurgery Ltd
0.59
-0.04
-6.35%
CALZF
Polynovo
0.86
-0.82
-48.81%
CHEOF
Cochlear
202.49
-20.09
-9.03%
AU:CYC
Cyclopharm Limited
1.08
-0.52
-32.50%
AU:EMV
EMvision Medical Devices Ltd.
1.80
-0.19
-9.55%
AU:4DX
4DMedical Ltd
0.26
-0.26
-50.00%

Aroa Biosurgery Ltd Corporate Events

Aroa Biosurgery Announces Director’s Interest Change
Jul 25, 2025

Aroa Biosurgery Ltd announced a change in the director’s interest, specifically involving Phillip McCaw. The change entails the lapse of 81,925 options due to expiry, impacting McCaw’s indirect holdings through various trusts. This adjustment reflects routine portfolio management and does not indicate any immediate strategic shifts for the company.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Director’s Change in Securities Interest
Jul 25, 2025

Aroa Biosurgery Limited announced a change in the interests of its director, John Pinion, as per the latest notice to the ASX. The change involved the lapse of 245,775 options exercisable at $0.75 due to expiry, which impacts the director’s holdings but does not alter the number of fully paid ordinary shares held. This update reflects routine adjustments in director holdings, which are part of standard corporate governance practices, and is unlikely to have significant implications for the company’s operations or market position.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Director’s Change in Securities Interest
Jul 25, 2025

Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically involving the lapse of options due to expiry. This change reflects a reduction in the number of options held by Director James McLean, which may impact his financial stake in the company but does not affect the overall number of fully paid ordinary shares he holds. Such changes are routine and part of the company’s regulatory compliance, with no immediate implications for stakeholders or the company’s market position.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Director’s Interest Change
Jul 25, 2025

Aroa Biosurgery Ltd has announced a change in the director’s interest, specifically noting the lapse of 3,132,525 options held by Director Brian Ward due to their expiry on July 23, 2025. This change reflects a reduction in Ward’s indirect holdings, which may impact the company’s governance dynamics and stakeholder perceptions, although it does not involve any financial consideration.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Cessation of Securities
Jul 25, 2025

Aroa Biosurgery Ltd announced the cessation of 5,104,050 securities due to the expiry of options without exercise or conversion as of July 23, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery to Host Webinar on Quarterly Results
Jul 22, 2025

Aroa Biosurgery Limited announced it will host a webinar to discuss its June Quarterly Results, which will be released on the same day. This event, featuring CEO Brian Ward and CFO James Agnew, aims to engage investors and interested parties, potentially impacting the company’s market positioning by providing insights into its financial performance and strategic direction.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Cessation of Securities Due to Unmet Conditions
Jul 11, 2025

Aroa Biosurgery Ltd announced the cessation of several securities due to unmet conditions, affecting options and performance share rights. This development may impact the company’s financial strategies and stakeholder interests, as it reflects a reevaluation of certain financial instruments within the organization.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Corrects Securities Lapse Misclassification
Jul 10, 2025

Aroa Biosurgery Ltd announced a correction to their previously released Appendix 3H regarding the cessation of securities, indicating a misclassification of 245,955 securities that were incorrectly lapsed from ARXAAH instead of ARXAAI. This correction does not affect other cessations included in the original document.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Schedules AGM and Director Elections
Jun 25, 2025

Aroa Biosurgery Ltd has announced that its Annual General Meeting will take place on August 20, 2025, where an election of directors will occur. The deadline for director nominations is set for July 2, 2025. This announcement is significant as it outlines the company’s governance timeline and provides stakeholders with the opportunity to influence the company’s leadership, potentially impacting its strategic direction and market positioning.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Expands Market Presence with New ASX Quotation
Jun 19, 2025

Aroa Biosurgery Ltd has announced the quotation of 132,979 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ARX. This move is part of the company’s strategy to enhance its market presence and provide additional liquidity for its stakeholders, potentially strengthening its position in the medical technology industry.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Updates on Director’s Securities Interest
Jun 17, 2025

Aroa Biosurgery Limited announced a change in the director’s interest, specifically regarding Brian Ward’s indirect interest in securities. The change involved the lapse of 591,768 options due to vesting conditions not being met, which impacts the director’s holdings but does not involve any acquisition or disposal of new securities. This update reflects the company’s compliance with ASX listing rules and provides transparency to stakeholders about changes in director interests.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Cessation of Securities
Jun 17, 2025

Aroa Biosurgery Ltd announced the cessation of certain securities due to unmet conditions, impacting a total of 2,608,699 securities. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Announces Director’s Shareholding Changes
Jun 11, 2025

Aroa Biosurgery Ltd has announced a change in the director’s interest notice, specifically involving John Diddams. The change includes the transfer of 100,000 fully paid ordinary shares from Galdarn Pty Ltd to Whitfield Investments Pty Ltd, with a total of 160,000 shares disposed of in an on-market sale valued at $77,474.96. This adjustment in shareholding reflects internal financial management and may impact the company’s stock distribution among stakeholders.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Transitions to New Share Registry Provider
May 30, 2025

Aroa Biosurgery Ltd has announced a change in its shareholder registry service provider from Boardroom Pty Ltd to Automic Pty Ltd, effective from June 2, 2025. This transition allows shareholders to manage their holdings more efficiently through Automic’s secure online investor portal, which offers features such as updating shareholder details and viewing transaction history. This change is expected to enhance shareholder engagement and streamline administrative processes, potentially improving the company’s operational efficiency and stakeholder satisfaction.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Releases Full-Year Results, Reinforces Commitment to Regenerative Healing
May 28, 2025

Aroa Biosurgery Ltd has released its full-year results for May 2025, highlighting its ongoing commitment to providing regenerative healing solutions. The announcement underscores the company’s strategic focus on advancing its product offerings and maintaining its position in the medical technology industry. This release is significant for stakeholders as it reflects Aroa’s continued growth and potential impact on the healthcare sector, particularly in the areas of wound care and tissue regeneration.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Reports Strong FY25 Results and Positive Outlook for FY26
May 28, 2025

Aroa Biosurgery Limited reported strong financial results for FY25, with a total revenue of NZ$84.7 million, marking a 23% growth from the previous year. The company achieved a positive operating cash flow and a significant improvement in EBITDA, reflecting robust sales of its Myriad and OviTex products. Looking ahead to FY26, Aroa anticipates continued revenue growth driven by Myriad sales and strategic investments in sales productivity and new product development. The company maintains a strong cash position with no debt, positioning it well for future growth.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Updates Full Year 2025 Financial Results Webinar Date
May 13, 2025

Aroa Biosurgery Limited announced an upcoming webinar to discuss its Full Year 2025 Financial Results, which will now be released on May 29, 2025, instead of the previously scheduled May 27. This update reflects the company’s commitment to transparency and engagement with investors and stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Australian Ethical Investment Becomes Substantial Holder in Aroa Biosurgery
May 1, 2025

Aroa Biosurgery Ltd has announced that Australian Ethical Investment Limited has become a substantial holder in the company, with a 5.01% voting power through 17,288,432 ordinary shares. This development signifies a notable investment in Aroa Biosurgery, potentially enhancing its market position and signaling confidence in its growth prospects, which may positively impact stakeholders and the company’s strategic initiatives.

Aroa Biosurgery Ltd: Advancing Regenerative Healing in Q4 FY’25
Apr 29, 2025

Aroa Biosurgery Ltd released its quarterly report for Q4 FY’25, highlighting its ongoing commitment to advancing regenerative healing technologies. The report, intended for educational purposes, emphasizes the company’s strategic focus on innovation and market expansion. While it does not serve as an investment prospectus, it underscores Aroa’s dedication to enhancing its market position and delivering value to stakeholders through its specialized medical products.

Aroa Biosurgery Reports Strong Financial Performance and Strategic Growth Initiatives
Apr 29, 2025

Aroa Biosurgery Limited reported its second consecutive quarter of positive cash flows from operations, with a cash flow of NZ$1.1 million and a strong cash balance of NZ$22.0 million. The company maintained its full-year FY25 revenue guidance, reflecting a 17-22% increase from FY24, and achieved record sales for its Myriad product line in March 2025. Aroa’s strategic initiatives include appointing a US-based Marketing Director to drive market growth and securing unique billing codes for its products to streamline reimbursement processes. The company’s operational progress and financial stability position it well for continued growth and investment in its product lines.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025